Aranscia's Suite of Laboratory and Technology Solutions to Support InterVenn's Commercialization ProgramSOUTH SAN FRANCISCO, Calif. and HOUSTON, Jan. 7, 2026…
Aranscia's Suite of Laboratory and Technology Solutions to Support InterVenn's Commercialization ProgramSOUTH SAN FRANCISCO, Calif. and HOUSTON, Jan. 7, 2026…
NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a…
NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a…
NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a…
Formal written minutes from the U.S. FDA confirms no major concerns identified for the planned Phase 3 PANDA study of…
CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (Nasdaq: GEHC) (“GE HealthCare”) announced today that it received notice on January 5, 2026, of…
AUSTIN, Texas, Jan. 6, 2026 /PRNewswire/ -- From wearable devices that catch health issues sooner to artificial intelligence (AI) tools…
STUART, Fla., Jan. 6, 2026 /PRNewswire/ -- Base Molecular Resonance™ Technologies (BMRT) today announced the successful completion of a multi-day test supporting…
Distinguished drug-development and biomarker leader to advance NAMkind™ scientific strategy, translational insights, and next-generation toxicology platformsSAN DIEGO, Jan. 06, 2026…